Clinical trial · Interventional
Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer
Etude ADC Apport de l'IRM Dans l'évaluation du Coefficient de Diffusion Apparent et prédiction de la réponse à la chimiothérapie néoadjuvante Dans le Cancer du Sein
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): We have finally no financial support and any patients have been included.
Summary
Brief summary (as posted)
The main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment sequence, the pathological response at the end of chemotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Assess the Variation of Apparent Diffusion Coefficient | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MRI (Magnetic resonance imaging) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Variation of apparent diffusion coefficient before / after a cycle of neoadjuvant chemotherapy or before / after modification of the treatment sequence and correlated with histologic response
- timeFrame
- One year
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age\> 18 years. * Patient suffering from a breast tumor, regardless of the stage and size * Patient requiring neoadjuvant chemotherapy * Patient has the ability to undergo 18F-FDG-PET at baseline, at end of cycle 1 and at the end of neoadjuvant treatment before surgery * Compulsory affiliation to a social security system. * Obtaining informed consent in writing, signed and dated. Exclusion Criteria: * Patient with cognitive or psychiatric disorders. * Patient deprived of liberty by a court or administrative. * Patient with signs against the achievement of MRI, mammography and ultrasound * Patient metastatic * Patient with prior chemotherapy, radiotherapy and hormone therapy for her breast cancer * Pregnant women, current lactation * Patient suffering from uncontrolled diabetes (\> 11 mmol / L)
References
Publications (0)
Data not yet available